Melphalan Hikma (Melphalan)

Melphalan acts as an alkylating agent that creates covalent cross‑links between DNA strands. These cross‑links block DNA replication and transcription, leading to cell‑cycle arrest and apoptosis of rapidly dividing cancer cells. Its mechanism is independent of specific cell‑surface receptors, allowing activity across many tumor types.

The dose of Melphalan Hikma is individualized by the prescribing oncologist based on the specific cancer indication, patient body surface area, renal and hepatic function, and prior treatment history. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Safety data for melphalan in pregnancy and lactation are limited, and the drug is considered potentially teratogenic. It is generally contraindicated during pregnancy and should be avoided while breastfeeding. Women of child‑bearing potential must use effective contraception throughout treatment and for a defined period afterward.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Melphalan Hikma. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Both melphalan and cyclophosphamide belong to the alkylating‑agent class, but melphalan is a nitrogen mustard derivative with a higher potency for cross‑linking DNA. Melphalan is often preferred for certain hematologic malignancies like multiple myeloma, whereas cyclophosphamide is more commonly used in breast cancer and lymphoma protocols. Their toxicity profiles differ, with melphalan showing greater myelosuppression.

Melphalan Hikma should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Maintaining the cold‑chain ensures stability and potency until preparation for intravenous administration.

Melphalan Hikma is supplied as a sterile powder for reconstitution and is administered intravenously. The reconstituted solution is infused over a period determined by the treating physician, typically ranging from several minutes to a few hours, depending on the dose and clinical protocol.

The most serious risks include severe myelosuppression leading to life‑threatening infections, secondary malignancies such as therapy‑related leukemia, pulmonary toxicity (interstitial pneumonitis), and organ toxicity in patients with compromised renal or hepatic function. Close monitoring and supportive care are essential to mitigate these risks.

Melphalan Hikma is contraindicated in patients with known hypersensitivity to melphalan or other alkylating agents, in individuals who are pregnant or breastfeeding, and in patients with severe uncontrolled infections or organ dysfunction that would preclude safe administration. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.